U.S. Viscosupplementation Market Research Report – Segmented By Product, End-user, and Region – Industry Analysis on Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 11480
Pages: 100

U.S. Viscosupplementation Market Size (2023 to 2028)

The viscosupplementation market size in the United States is forecasted to grow at a significant CAGR during the forecast period and was worth USD 2.1 billion in 2022.

The growing patient population suffering from osteoarthritis in the U.S. and increasing demand for non-surgical treatment are propelling the U.S. viscosupplementation market growth. According to the Centers for Disease Control and Prevention (CDC), an estimated 34.5 million adults in the United States suffer from osteoarthritis each year. People who suffer from osteoarthritis usually have less hyaluronic acid in the joints, leading to pain, stiffness, swelling, and difficulty in movement. In recent years, people have shown interest in non-surgical treatment due to fear of surgical procedures and expensive treatment costs.

Increasing advancements in the development of hyaluronic acid-based therapies are further promoting the viscosupplementation market growth in the United States. The key market participants are focusing on developing the treatment with hyaluronic acid, which help for fast relief from knee pain for every age group. In addition, researchers are increasing different ways of treatment to slow down knee pain disorder expansion.

The increasing geriatric population is expected to fuel the growth of the viscosupplementation market in the U.S. during the forecast period. Nearly 100 million Americans suffer from knee pain, the second most common chronic pain in the United States. Knee pain can be caused due to diabetes, obesity, and other reasons. People 60 years of age are more likely to face severe knee problems and need treatment. Thus, the growing aging population suffering from severe knee pain is expected to generate demand for viscosupplementation. Furthermore, growing R&D activities, increasing investments by the U.S. government, favorable reimbursement policies, increasing product launches in the market, and a growing adoption rate of viscosupplementation in the U.S. are driving the market growth.

The presence of alternative knee therapies is the major restrain of the market growth in the United States. Along with this high cost of Viscosupplementation treatment, lack of awareness of the treatment about Viscosupplementation and lack of skilled professionals for the treatment in most of the hospitals are the factors that hamper the market growth. In addition, side effects after the treatment, such as pain, swelling, heat, and redness, may challenge the market growth.

However, alternative knee therapies, high costs associated with viscosupplementation, lack of awareness, and lack of skilled professionals hamper the market growth. In addition, side effects associated with the treatment, such as pain, swelling, heat, and redness, negatively impact the market’s growth rate.

This research report on the U.S. viscosupplementation market has been segmented and sub-segmented into the following categories.

By Product:

  • Single Injection
  • Three Injection
  • Five Injection

By End-Use:

  • Hospitals
  • Orthopedic Clinic/ Ambulatory Surgical Centers (ASCs)

By Country:

  • The United States

Regionally, the U.S. plays a vital role in the global viscosupplementation market. In 2022, the U.S. market held a significant share of the North American region. The increasing number of product approvals by the FDA and growing healthcare spending by the U.S. population are favoring the viscosupplementation market in this country. In addition, the growing aging population in the U.S. is expected to boost the usage of viscosupplementation in the United States in the coming days. However, nearly 20% of people in the U.S. are aging more than 45 years and suffer from knee osteoarthritis.

On the other hand, the Canadian viscosupplementation market is expected to hold a considerable share of the North American market in the coming years. Recently, the Arthroscopy Association of Canada (AAC) published guidelines for treating knee pain. The viscosupplementation market participants in Canada have taken steps towards developing injection combinations for knee pain, such as osteoarthritis. In Canada, 25% suffer from knee osteoarthritis, which increases the clinical outcome of the Viscosupplementation treatment. The availability of Viscosupplementation treatment in many hospitals and drugs in the local stores also helps to raise market growth. Nuvo Pharmaceuticals Inc., a Canadian company, launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada to treat pain relief and improve joint functionality in patients with degenerative knee diseases.


Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Chungai Pharmaceutical Co., Ltd., OrthogenRx Inc., and Mylan N.V. are expected to play the leading role in the U.S. viscosupplementation market.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample